Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced Nasopharyngeal Carcinoma Yahua Zhong Department of Chemo-radiotherapy Oncology Zhongnan Hospital, Wuhan University Hubei Cancer Study Center, China

Objective To evaluate the feasibility and efficacy of docetaxel and cisplatin neoadjuvant chemotherapy followed by intensity-modulated radiotherapy with concurrent cisplatin in patients with locally advanced nasopharyngeal carcinoma

Eligibility Criteria Previously untreated Patients with histologically confirmed stage Ⅲ –IVB(1997 American Joint Committee on Cancer Staging) NPC ECOG 0 or 1 Age ≥ 18 years Normal bone marrow, hepatic and renal function

Materials and Methods W1W3W2W5W4W7W6W8W11W1 0 W9W1 2 W1 3 2 cycles of DCIMRT with concurrent DDP Docetaxel 75mg/m 2 Cisplatin 75mg/m 2 IMRT 72Gy/2.18Gy/33F/ Cisplatin 75mg/m 2

Results Among 46 patients, 45 completed 2 cycles schedule neoadjuvant chemotherapy All patients completed the IMRT and 2 cycles concurrent DDP chemotherapy on schedule

Table 1. The incidence of acute toxicities during neoadjuvant chemotherapy

Table 2. The incidence of acute toxicities during concurrent chemo-radiotherpy

Table 3. The incidence of later toxicities

Table 4. The tumor objective response

Results Median follow-up time of 26 months, One patients experienced nasopharyngeal recurrence and four patients developed distant metastasis The 3-year overall survival rate and progression-free survival rate were 94.1% and 72.7%, respectively

Conclusion Neoadjuvant docetaxel/cisplatin followed by IMRT with concurrent cisplatin was well feasible and effective in treating locally advanced nasopharyngeal carcinoma. Further investigation to test this strategy is warranted

Thank you